PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDinoprostone
Dinoprostone
Cervidil, Prepidil (dinoprostone) is a small molecule pharmaceutical. Dinoprostone was first approved as Prostin e2 on 1982-01-01. It is used to treat fetal death, gestational trophoblastic disease, and uterine neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Cervidil, Prepidil (discontinued: Prostin e2)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dinoprostone
Tradename
Company
Number
Date
Products
CERVIDILFerring PharmaceuticalsN-020411 RX1995-03-30
1 products, RLD, RS
PREPIDILPfizerN-019617 RX1992-12-09
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cervidilNew Drug Application2023-06-02
prepidilNew Drug Application2025-03-27
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
G02: Other gynecologicals in atc
G02A: Uterotonics
G02AD: Prostaglandins, oxytocics
G02AD02: Dinoprostone
HCPCS
No data
Clinical
Clinical Trials
182 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cesarean sectionD00258511
Obstetric deliveryD03686111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cervical ripeningD020070426
Induced laborD007751213
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDinoprostone
INNdinoprostone
Description
Prostaglandin E2 is prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. It has a role as an oxytocic, a human metabolite and a mouse metabolite. It is a conjugate acid of a prostaglandin E2(1-).
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O
Identifiers
PDB
CAS-ID363-24-6
RxCUI
ChEMBL IDCHEMBL548
ChEBI ID15551
PubChem CID5280360
DrugBankDB00917
UNII IDK7Q1JQR04M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,877 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,276 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use